3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Optic Nerve Glioma
1
Neoplasms, Unknown Primary
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Diffuse Intrinsic Pontine Glioma
1
Astrocytoma
1
Interventions
Fluorouracil
8
Oxaliplatin
7
Leucovorin
6
Irinotecan
6
Gemcitabine
5
fludarabine
3
aldesleukin
3
Pemetrexed
3
Nivolumab
3
Cyclophosphamide
3
Cetuximab
3
Capecitabine
3
5,10-methylenetetrahydrofolic acid
3
dehydroftorafur
2
cobimetinib
2
Specimen Handling
2
Panitumumab
2
Interleukin-2
2
Docetaxel
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
tivozanib
1
sodium propionate
1
rucaparib
1
rilotumumab
1
repotrectinib
1
regorafenib
1
pralsetinib
1
pertuzumab
1
pembrolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Gastrointestinal Neoplasms
×
Mebendazole
×
Clear all
NCT03628079
2020-01-22
RepoMeb
Repos Pharma
Phase 1/2
Terminated
11 enrolled